Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Beckman Coulter Life Sciences and IncellDx have signed a distribution agreement which focuses exclusively on clinical researchers in mainland China, Hong Kong and Taiwan working on the Human Papilloma Virus (HPV) and cancer.
Subscribe to our email newsletter
The commercial partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification.
IncellDx’s next generation (3Dx) investigational molecular assay used to quantify HPV E6, E7 mRNA in single cells has been specially optimized to run on Beckman Coulter’s innovative CytoFLEX flow cytometry system.* The high throughput system instrument has the precision to integrate E6, E7 mRNA overexpression with the measurement of cell cycle and cell proliferation.
Beckman Coulter Flow Cytometry Business Unit VP and general manager Mario Koksch said: "The CytoFLEX easily fits into today’s rapid workflow in research cytometry – combining ease of use with exceptional analytical performance and built-in automation.
"This innovative partnership with IncellDx enables us to expand our product offerings in clinical research applications, further strengthening the company’s growing infectious diseases portfolio."
IncellDx CEO Bruce Patterson said: "We are excited about this opportunity to bring molecular testing to the flow cytometry field in a region of the world with a great appetite for innovation in the molecular space. The hallmark of cancer research is the quantification of oncogenes E6 and E7 in cells from the cervix, anus, or head and neck. However, as cytology samples contain a heterogeneous mixture of normal and abnormal cells, it is critical that we are able to carry out quantification at the single cell level."